Table 2.
Ongoing clinical studies combining AA and immunotherapies in NSCLC.
| Study Name | Targeting Agents | Comparison | Phase | Primary Endpoint | Therapy Setting | Status * | NCT Number |
|---|---|---|---|---|---|---|---|
| CheckMate 012 | bevacizumab + nivolumab | bevacizumab | I | PFS, OS | First line maintenance | Active Not recruiting | NCT01454102 |
| N.a. | ramucirumab + pembrolizumab | ramucirumab | I | PFS, OS | Inoperable patients | Recruiting | NCT02443324 |
| IMpower150 | Atezolizumab + bevazicumab carboplatin + paclitaxel | Atezolizumab + carboplatin + paclitaxel | III | PFS, OS | First line (Stage IV) | Recruiting | NCT02366143 |
| N.a. | atezolizumab + bevacizumab | / | Ib | Safety | First line | Active Not recruiting | NCT01633970 |
| N.a. | pembrolizumab + nintedanib | / | Ib | MTD of nintedanib, Safety | First line | Recruiting | NCT02856425 |
| N.a. | nivolumab + nintedanib | / | Ib | Safety | Second line | Not recruiting | TBA |
| N.a. | pembrolizumab + paclitacel + bevazicumab | Pembrolizumab + paclitacel | I/II | Clinical efficacy and safety | First line (Stage IIIB/IV) | Recruiting | NCT02039674 |
* status according to https://clinicaltrials.gov/, accessed on 8 July 2017. OS, overall survival; PFS, progression free survival; N.a., not assessed; MTD, maxium tolerated dose; TBA, to be announced; NCT, clinicaltrials.gov registry number.